精神分裂症患者颞上回大麻素受体密度无变化。
No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.
作者信息
Deng Chao, Han Mei, Huang Xu-Feng
机构信息
School of Health Sciences, University of Wollongong, Wollongong, NSW 2522, Australia.
出版信息
Neurosci Bull. 2007 Nov;23(6):341-7. doi: 10.1007/s12264-007-0051-9.
Abstract
OBJECTIVE
In recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, we investigated the binding density of cannabinoid CB1 receptors in the STG of schizophrenia patients compared to control subjects.
METHODS
Quantitative autoradiography was used to investigate the binding densities of [(3)H]SR141716A (a selective antagonist) and [(3)H]CP-55940 (an agonist) to the CB1 receptors in the STG. Post-mortem brain tissue was obtained from the NSW Tissue Resource Centre (Australia).
RESULTS
Contrasting to previous findings in the alterations of CB1 receptor densities in the prefrontal, anterior and posterior cingulate cortex of schizophrenia, which were suggested to be associated to impairment of cognition function, no significant difference was found between the schizophrenia and control cases in both [(3)H]SR141716A and [(3)H]CP-55940 binding.
CONCLUSION
We suggest that CB1 receptors in the STG are not involved in the pathology of schizophrenia and the auditory hallucination symptom of this disease.
摘要
目的
近年来，已发现精神分裂症患者的内源性大麻素系统存在异常变化。颞上回（STG）与精神分裂症的病理生理学密切相关，尤其是在幻听方面。在本研究中，我们调查了精神分裂症患者与对照受试者相比，颞上回中大麻素CB1受体的结合密度。
方法
采用定量放射自显影术研究[(3)H]SR141716A（一种选择性拮抗剂）和[(3)H]CP - 55940（一种激动剂）与颞上回中CB1受体的结合密度。死后脑组织取自新南威尔士州组织资源中心（澳大利亚）。
结果
与先前在精神分裂症患者前额叶、前扣带回和后扣带回皮质中CB1受体密度改变的研究结果相反（这些改变被认为与认知功能损害有关），在[(3)H]SR141716A和[(3)H]CP - 55940结合方面，精神分裂症患者与对照组之间未发现显著差异。
结论
我们认为颞上回中的CB1受体不参与精神分裂症的病理过程以及该疾病的幻听症状。
相似文献
1
No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.精神分裂症患者颞上回大麻素受体密度无变化。
Neurosci Bull. 2007 Nov;23(6):341-7. doi: 10.1007/s12264-007-0051-9.
2
Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia.精神分裂症患者颞上回中γ-氨基丁酸A受体密度增加。
Exp Brain Res. 2006 Jan;168(4):587-90. doi: 10.1007/s00221-005-0290-9. Epub 2005 Dec 16.
3
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.在精神分裂症患者的前扣带回皮质中，选择性拮抗剂[3H]SR141716A与大麻素CB1受体的结合增加。
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60. doi: 10.1016/j.pnpbp.2003.11.005.
4
Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study.精神分裂症患者颞上回 5-羟色胺 2A 受体密度降低——一项尸检研究。
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 1;33(5):867-71. doi: 10.1016/j.pnpbp.2009.04.010. Epub 2009 Apr 21.
5
Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia.精神分裂症患者颞上回毒蕈碱受体密度降低。
J Neurosci Res. 2005 Sep 15;81(6):883-90. doi: 10.1002/jnr.20600.
6
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.精神分裂症患者后扣带回皮质中大麻素受体密度增加。
Exp Brain Res. 2006 Jul;172(4):556-60. doi: 10.1007/s00221-006-0503-x. Epub 2006 May 19.
7
Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.精神分裂症、双相情感障碍和重度抑郁症患者前扣带回皮质中CB1大麻素受体的表达
J Neural Transm (Vienna). 2007;114(8):1055-63. doi: 10.1007/s00702-007-0660-5. Epub 2007 Mar 19.
8
Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia.精神分裂症患者上颞叶皮层中 DARPP-32 表达的改变。
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1139-43. doi: 10.1016/j.pnpbp.2011.03.016. Epub 2011 Mar 29.
9
5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.5-羟色胺1A和5-羟色胺2A受体信使核糖核酸及结合位点密度在精神分裂症中存在差异改变。
Neuropsychopharmacology. 1996 Nov;15(5):442-55. doi: 10.1016/S0893-133X(96)00053-X.
10
Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study.精神分裂症患者颞叶中D2多巴胺受体模式的破坏。一项尸检研究。
Arch Gen Psychiatry. 1997 Jul;54(7):649-58. doi: 10.1001/archpsyc.1997.01830190077008.
引用本文的文献
1
Endocannabinoid system in psychotic and mood disorders, a review of human studies.精神障碍和心境障碍中的内源性大麻素系统：人类研究综述。
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110096. doi: 10.1016/j.pnpbp.2020.110096. Epub 2020 Sep 6.
2
Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.使用大麻和不使用大麻的患者是不同的群体吗？ 旨在了解精神障碍患者中使用大麻的神经生物学。
J Psychopharmacol. 2018 Aug;32(8):825-849. doi: 10.1177/0269881118760662. Epub 2018 Mar 29.
3
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.精神分裂症患者大脑中大麻素受体可用性降低
Biol Psychiatry. 2016 Jun 15;79(12):997-1005. doi: 10.1016/j.biopsych.2015.08.021. Epub 2015 Aug 29.
4
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.放射性标记的反向激动剂与大麻素 CB1 受体的结合在精神分裂症患者中增加。
Schizophr Res. 2012 Nov;141(2-3):185-8. doi: 10.1016/j.schres.2012.07.021. Epub 2012 Aug 19.
5
Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies.精神分裂症患者中使用大麻对人脑结构的影响：结合体内结构神经影像学和尸体研究的系统综述。
Curr Pharm Des. 2012;18(32):5070-80. doi: 10.2174/138161212802884861.
6
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.跨膜结构域神经调节蛋白 1 突变型小鼠中海马大麻素受体 1 表达缺失对神经行为的影响
PLoS One. 2012;7(4):e34129. doi: 10.1371/journal.pone.0034129. Epub 2012 Apr 3.
7
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.与奥氮平引起的体重增加相关的黑素细胞皮质素能、GABA 能和大麻素神经递质的改变。
PLoS One. 2012;7(3):e33548. doi: 10.1371/journal.pone.0033548. Epub 2012 Mar 16.
8
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.内源性大麻素系统与精神病学：探寻有害及潜在治疗作用的神经生物学基础
Front Behav Neurosci. 2011 Oct 5;5:63. doi: 10.3389/fnbeh.2011.00063. eCollection 2011.
9
Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.偏执型精神分裂症的特征是背外侧前额叶皮层中 CB1 受体结合增加。
Neuropsychopharmacology. 2011 Jul;36(8):1620-30. doi: 10.1038/npp.2011.43. Epub 2011 Apr 6.
10
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.大麻素 CB1 受体在前额叶皮层中的免疫反应：精神分裂症与重度抑郁症的比较。
Neuropsychopharmacology. 2010 Sep;35(10):2060-71. doi: 10.1038/npp.2010.75. Epub 2010 Jun 16.
本文引用的文献
1
Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia.精神分裂症患者后扣带回皮质中毒蕈碱和GABA受体结合的改变。
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):225-33. doi: 10.1016/j.pnpbp.2006.07.004. Epub 2006 Aug 9.
2
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.精神分裂症患者后扣带回皮质中大麻素受体密度增加。
Exp Brain Res. 2006 Jul;172(4):556-60. doi: 10.1007/s00221-006-0503-x. Epub 2006 May 19.
3
Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.
Expert Opin Ther Targets. 2006 Apr;10(2):203-10. doi: 10.1517/14728222.10.2.203.
4
Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.氯氮平降低大鼠伏隔核中[3H] CP 55940与大麻素1受体的结合。
Naunyn Schmiedebergs Arch Pharmacol. 2005 May;371(5):428-33. doi: 10.1007/s00210-005-1074-2. Epub 2005 Jul 2.
5
New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia.内源性大麻素与大麻研究的新视角：大麻素受体与精神分裂症
J Pharmacol Sci. 2004 Dec;96(4):376-81. doi: 10.1254/jphs.fmj04003x4.
6
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.急性精神分裂症患者脑脊液中花生四烯酸乙醇胺水平升高，且与精神症状呈负相关。
Neuropsychopharmacology. 2004 Nov;29(11):2108-14. doi: 10.1038/sj.npp.1300558.
7
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.在精神分裂症患者的前扣带回皮质中，选择性拮抗剂[3H]SR141716A与大麻素CB1受体的结合增加。
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60. doi: 10.1016/j.pnpbp.2003.11.005.
8
Neuroanatomy of "hearing voices": a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia.“幻听”的神经解剖学：一种与精神分裂症幻听相关的额颞叶脑结构异常。
Cereb Cortex. 2004 Jan;14(1):91-6. doi: 10.1093/cercor/bhg107.
9
Morphology of the lateral superior temporal gyrus in neuroleptic nai;ve patients with schizophrenia: relationship to symptoms.未服用抗精神病药物的精神分裂症患者颞上回外侧的形态学：与症状的关系
Schizophr Res. 2003 Apr 1;60(2-3):173-81. doi: 10.1016/s0920-9964(02)00299-2.
10
Cannabis and psychosis.大麻与精神病。
Curr Psychiatry Rep. 2002 Jun;4(3):191-6. doi: 10.1007/s11920-002-0026-5.
Zotero 插件